Focus:
AI
-
5 December 2019
Novartis partners with Amazon for digital boost to manufacturing
Novartis has collaborated with Amazon Web Services (AWS) to digitally transform the manufacturing, supply chain and delivery of its medicines using cloud services.
-
17 October 2019
Healx raises funds to develop rare disease treatments
UK-based company Healx has raised $56m in a Series B funding round for the development of rare disease treatments that are identified using artificial intelligence (AI) technology called Healnet.
-
3 October 2019
Novartis teams up with Microsoft for AI drug development
Novartis has allied with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and commercialisation of medicines.
-
26 September 2019
ESMO 2019: Seven promising digital health intervention companies participating in ESMO
Pharmaceutical Technology lists seven promising digital health intervention companies that are participating in the European Society of Medical Oncology (ESMO) Congress 2019.
-
12 September 2019
Atomwise inks four new deals for AI-based drug discovery
US-based Atomwise has formed four new alliances to leverage its artificial intelligence (AI) technology for the discovery of new drugs across various therapeutic areas.
-
3 September 2019
Insilico Medicine develops new AI drug discovery system
Insilico Medicine has developed an artificial intelligence (AI)-powered system to facilitate the creation of therapeutic molecules.
-
20 August 2019
Mateon and PointR to merge into AI-driven oncology firm
Immuno-oncology company Mateon Therapeutics has signed a definitive agreement to merge with PointR Data, a computer and artificial intelligence (AI) company, to form an AI-driven firm focused on cancer treatment.
-
19 August 2019
Juvenescence closes $100m series B round for longevity therapies
UK-based life sciences firm Juvenescence has announced a $100m series B financing round to support the development of artificial intelligence (AI)-based therapeutics and technologies for ageing diseases.
-
2 August 2019
Sensyne Health and Bayer partner on AI drug development
Sensyne Health, a UK-based clinical artificial intelligence (AI) technology firm, has collaborated with German pharmaceutical company Bayer to accelerate the development of new heart therapies.
-
16 July 2019
Recursion secures funds to support AI-based drug discovery
Artificial intelligence (AI) drug discovery firm Recursion Pharmaceuticals, has secured $121m in a series C funding round led by the Scottish Mortgage Investment Trust.
Close
Close
Close
Go Top
